This podcast episode explores the use of surrogate endpoints versus patient-important clinical outcomes in medical and psychological research studies, highlighting their role in accelerating trials while cautioning against over-reliance. It presents advantages such as faster, less expensive studies alongside critical limitations, including frequent failures to predict real clinical benefit as seen in cardiovascular, oncology, and Alzheimer’s research. Listeners receive a balanced framework for critically appraising research that employs surrogate markers.

We put the "obesity shrinks your brain" headlines under the microscope to separate causal reality from confounding variables. This episode navigates the neurodegeneration debate, questioning if the data holds up or if we're seeing another case of correlation being sold as causation. Join us as we strip away the spin to see what the evidence actually says about the relationship between weight and white matter.

In 2025, a viral study claiming that 95% of corporate AI pilots were failing sent the Nasdaq into a tailspin—but there was one problem: the math was 100% wrong. We join Rob Wiblin to dissect how a flawed report managed to hijack the global AI narrative and what the evidence actually says about the success of generative AI in the enterprise. Learn how to spot "data torture" and why the real story of AI integration is far more optimistic than the headlines suggest.

A major 2026 review in the journal Carcinogenesis claims nicotine vapes are “likely” to cause lung and oral cancers based on DNA damage, inflammation, and mouse tumors. Public-health experts on the other side call the paper misleading, arguing vaping remains far safer than smoking and a proven tool for quitting. We examine both arguments, expose the limitations of the studies on each side, and end with practical, no-nonsense advice for listeners.

This episode examines the heated debate between the Cochrane Review and The Lancet on anti-amyloid drugs for Alzheimer’s. We break down the modest benefits, real risks, and methodological differences between older and newer treatments. A balanced, evidence-based analysis for patients, families, and clinicians seeking clarity on this controversial topic.

In this episode, we examine the “Rat Study Problem” — the persistent challenge in biomedical research where treatments that succeed dramatically in mice frequently fail when tested in humans. The discussion explores biological differences in metabolism, immune response, disease progression, and environmental factors that limit the predictive value of rodent models. It highlights the high cost of translation failures and the growing need for more sophisticated, human-relevant research approaches to accelerate genuine medical breakthroughs.

Most people consume scientific research through headlines—but those headlines often distort study design, exaggerate results, and hide critical limitations like small sample sizes, animal models, and surrogate markers. In this episode, we break down the most common ways research is misrepresented in the media, including the misuse of relative risk, correlation vs. causation errors, and misleading health claims. Learn how to evaluate studies like a professional and develop the critical thinking skills needed to separate evidence-based science from media spin.